These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10562670)

  • 1. [Update on the pharmacological interactions of systemic antifungal agents].
    Viudes A; Pemán J; Cantón E; Ubeda P; Gobernado M
    Rev Esp Quimioter; 1999 Jun; 12(2):107-15. PubMed ID: 10562670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of systemic fungal infections: alternatives to itraconazole.
    Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal treatment in pediatric patients.
    Zaoutis TE; Benjamin DK; Steinbach WJ
    Drug Resist Updat; 2005 Aug; 8(4):235-45. PubMed ID: 16054422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The activity of systemic antimycotic drug combinations].
    Viudes A; Pemán J; Cantón E; López-Ribot J; Gobernado M
    Rev Esp Quimioter; 2001 Mar; 14(1):30-9. PubMed ID: 11376347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms of resistance to antifungal agents].
    Makimura K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():466-70. PubMed ID: 17455664
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of amphotericin B and flucytosine against fluconazole-resistant Candida inconspicua clinical isolates.
    Majoros L; Kardos G; Feiszt P; Szabó B
    J Antimicrob Chemother; 2005 Jul; 56(1):253-4. PubMed ID: 15911550
    [No Abstract]   [Full Text] [Related]  

  • 7. Antifungal resistance in pathogenic fungi.
    Perea S; Patterson TF
    Clin Infect Dis; 2002 Nov; 35(9):1073-80. PubMed ID: 12384841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal agents. Part I. Amphotericin B preparations and flucytosine.
    Patel R
    Mayo Clin Proc; 1998 Dec; 73(12):1205-25. PubMed ID: 9868423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of agents used in the treatment of pulmonary mycoses.
    Borgers M; Vanden Bossche H; Cauwenbergh G
    Clin Chest Med; 1986 Sep; 7(3):439-52. PubMed ID: 3021382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions with systemic antifungals in clinical practice.
    Depont F; Vargas F; Dutronc H; Giauque E; Ragnaud JM; Galpérine T; Abouelfath A; Valentino R; Dupon M; Hébert G; Moore N
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1227-33. PubMed ID: 17879355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant drug interactions of current antifungal agents.
    Gubbins PO; Heldenbrand S
    Mycoses; 2010 Mar; 53(2):95-113. PubMed ID: 20002883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Has antifungal susceptibility testing come of age?
    Rex JH; Pfaller MA
    Clin Infect Dis; 2002 Oct; 35(8):982-9. PubMed ID: 12355386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
    Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
    J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic treatment of systemic candidiasis in newborns.
    Serra G; Mezzano P; Bonacci W
    J Chemother; 1991 Jan; 3 Suppl 1():240-4. PubMed ID: 12041777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
    Te Dorsthorst DT; Mouton JW; van den Beukel CJ; van der Lee HA; Meis JF; Verweij PE
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basis of antifungal chemotherapy].
    Arai T; Uno H
    Nihon Saikingaku Zasshi; 1983; 38(2):525-48. PubMed ID: 6350637
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera.
    Vitale RG; Afeltra J; de Hoog GS; Rijs AJ; Verweij PE
    J Antimicrob Chemother; 2003 May; 51(5):1297-300. PubMed ID: 12697648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
    Brüggemann RJ; Alffenaar JW; Blijlevens NM; Billaud EM; Kosterink JG; Verweij PE; Burger DM
    Clin Infect Dis; 2009 May; 48(10):1441-58. PubMed ID: 19361301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.